Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

nogapendekin alfa inbakicept-pmln

View Patient Information
A mutated form of the cytokine interleukin (IL)-15 (IL-15N72D), with potential immunomodulating and antineoplastic activities. Upon administration, nogapendekin alfa binds to the IL-15 receptor on natural killer (NK) and CD8+ T lymphocytes, which activates and increases the levels of NK cells and memory T cells. This may increase tumor cell killing and decrease tumor cell proliferation. IL-15 regulates CD8+ T and NK cell development, activation and proliferation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:IL-15N72D-IL-15RaSU/Fc
inbakicept nogapendekin alfa fusion complex
nogapendekin alfa inbakicept
superagonist interleukin-15:interleukin-15 receptor alphaSu/Fc fusion complex Alt-803
US brand name:Anktiva
Abbreviation:IL-15N72D/IL-15Ra-Fc
Code name:ALT 803
ALT-803
ALT803
N 803
N-803
N803
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search